Published in final edited form as:

J Am Chem Soc. 2013 September 4; 135(35): . doi:10.1021/ja407739y.

Bioconjugation by Native Chemical Tagging of C–H Bonds

Qianghui Zhou[†], Jinghan Gui[†], Chung-Mao Pan[†], Earl Albone[‡], Xin Cheng[‡], Edward M. Suh[§], Luigi Grasso[‡], Yoshihiro Ishihara[†], and Phil S. Baran^{†,*}

[†]Department of Chemistry, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037

[‡]Morphotek, Inc., 210 Welsh Pool Road, Exton, Pennsylvania 19341

[§]Next Generation Systems, Eisai, Inc., 4 Corporate Drive, Andover, Massachusetts 01810

Abstract

A general C–H functionalization method for the tagging of natural products and pharmaceuticals is described. An azide-containing sulfinate reagent allows the appendage of azidoalkyl chains onto heteroaromatics, the product of which can then be attached to a monoclonal antibody by a “click” reaction. This strategy expands the breadth of bioactive small molecules that can be linked to macromolecules in a manner that is beyond the scope of existing methods in bioconjugation to permit tagging of the “seemingly untaggable.”

Determining the mode of action of medicinal compounds by bioconjugation is an essential tool in chemical biology.¹ Bioconjugation requires a covalent and/or non-covalent linkage of the small-molecule drug with macromolecular tags including antibodies, nucleic acids, and receptor-binding proteins.² This process of derivatization often involves “click” chemistry,³ with the most popular method arguably being the azide–alkyne cycloaddition:⁴ a functional group on the lead compound is attached to a linker with an alkyne (or alternatively, an azide), which is then reacted with a macromolecular tag with a pendant azide (or alternatively, an alkyne). Typically, only conventional functional groups can be tagged by linkers with “clickable” groups (Figure 1A),^{5a–5e} but in a recent elegant example, Romo’s group has functionalized activated C–H bonds (allylic C–H, benzylic C–H and C–H to a heteroatom) to tag natural products.^{5f} Although many medicinal agents contain traditionally “taggable” functional groups such as heteroatom–H bonds^{5a–5c} and bonds,^{5e} some compounds [such as camptothecin (**1**) and buspirone (**2**)] present the challenge of not having any apparent chemical handles (Figure 1B). Herein, we show the invention of a reagent that enables the tagging of unactivated C–H bonds in bioactive heteroarenes for use in bioconjugation. This powerful native chemical tagging technique takes place in water and in the absence of protecting groups.

Our laboratory has been interested in assembling a toolkit of (fluoro)alkanesulfinate reagents for heteroaromatic systems.⁶ Such reagents form radicals *in situ* via an oxidative process, resulting in a formal C–H functionalization. For the purpose of bioconjugation, an alkyl linker bearing an azide moiety was desired. Considering the mild reaction conditions involved in this chemistry, it was conjectured that the relatively sensitive azide moiety would survive the heterocycle functionalization reaction. Thus, a sulfinate reagent bearing

Corresponding Authors: pbaran@scripps.edu (P.S.B.).

The authors declare no competing financial interest.

Supporting Information. Experimental procedures and analytical data (¹H and ¹³C NMR, MS) for all new compounds. This material is available free of charge *via* the Internet at <http://pubs.acs.org>.

an azide moiety, sodium (difluoroalkylazido)sulfinate (DAAS-Na; **3**), was designed (Figure 1C). The synthesis, reactivity and application of this reagent (which has been commercialized through Sigma–Aldrich) are described below.

The synthesis of this reagent begins with chlorinated (fluoroalkylsulfonyl)pyridine **4**, which was synthesized previously^{6c} in 3 steps from commercially available 2-mercaptopyridine (Figure 2A). Displacement of the chloride with an azide, followed by removal of the pyridine moiety using sodium ethanethiolate, provided DAAS-Na (**3**) in 78% yield over two steps. Sodium sulfinate reagent **3** was then used in a heteroarene functionalization reaction that involves ZnCl₂ and TsOH•H₂O as acid additives and ^tBuOOH as an oxidant. Although various organic solvents have been used previously for sulfinate radical functionalizations,^{6b} either CH₂Cl₂:H₂O or DMSO:H₂O (2.5:1) was sufficient for the reaction of DAAS-Na (**3**). These optimized reaction conditions were used throughout the examination of the substrate scope.

The strength of this chemistry lies in the ability to append azide-terminated linkers to heteroarene moieties in complex natural products bearing sensitive functional groups (Figure 2B). A representative natural product example is depicted with camptothecin (**1**). While the tertiary alcohol in **1** is likely to be too hindered for chemical derivatization, sulfinate **3** allows for the radical functionalization of the quinoline moiety to give the corresponding azido-containing product in 42% isolated yield. Scepterin (**6**), a cell motility inhibitor⁷ that can be accessed by total synthesis,⁸ was also functionalized to give a single product in 35% yield. Papaverine (**7**), an antispasmodic agent, has two sites of reactivity, giving rise to products in 16 and 17% yields, respectively. Known pharmaceutical agents of varying complexity can be equally functionalized using this method (Figure 2C). A range of pyridine-containing drugs (**8–16**) can be functionalized at their C2 and/or C4 positions, which are the most susceptible sites for nucleophilic radical attack. Azine-based pharmaceuticals (**2**, **17**, **18**), and medicinal agents containing other heterocyclic cores (**19–22**) were also functionalized with DAAS-Na (**3**). It is notable that alcohol, amine, amide, amidine, hydrazide, sulfonamide, and alkene functional groups were tolerated in this reaction. The multiple sites of C–H activation for many of these compounds allow the exploration of structure-activity relationships for these molecules as well as the opportunity to evaluate optimal linker attachment with respect to bioactivity.

The main goal of this research program is realized by appending macromolecular tags to these bioactive, small-molecule agents. To this end, the synthesized azide-linked medicinal agents were reacted with a dibenzylazacyclooctyne-containing monoclonal antibody in a copper-free azide–alkyne cycloaddition (Figure 3A).⁹ Two methods of bioconjugation were employed, namely the conventional and high-throughput methods (see Supporting Information for details). The generated drug–antibody conjugates were verified by mass spectrometry, confirming the feasibility of this C–H functionalization approach to bioconjugation (Figure 3B). Future studies will examine whether antibody–drug conjugates generated using this strategy can exert cytotoxicity when armed with potent cytotoxic small molecules.

Although this method of compound tagging through C–H functionalization extends the scope of existing methods in bioconjugation, it is not without its limitations. Reaction yields can be low and mixtures of regioisomeric products may be obtained, which may render the product purification process difficult. However, the mild (room temperature or 50 °C) and convenient (open air, aqueous solvent) reaction conditions as well as the one-step nature of this chemical tagging method outweigh the occasional drawbacks.

In summary, this work demonstrates an approach to the native chemical tagging of small molecules at seemingly inert C–H bonds. This method holds great potential for labeling and bioconjugation of molecules that do not present functional groups for conventional reactions. Studies demonstrating the enhanced efficacy of these medicinal agents will be reported in due course.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Financial support for this work was provided by NIH/NIGMS (GM-106210), Morphotek, Eisai, Inc. and SIOC (postdoctoral fellowship to Q. Z. and J. G.). The authors thank J. Eric Carlson for providing materials to demonstrate linker attachments, as well as Ryan Gianatassio, Alessandro Ruffoni, Darryl D. Dixon and Erik Daa Funder for technical contributions to the early stages of this project.

References

1. For an early review in bioconjugation targeting monoclonal antibodies, see: Koppel GA. Bioconjugate Chem. 1990; 1:13–23. For recent reviews in enzyme profiling using bioconjugated chemical probes, see: Evans MJ, Cravatt BF. Chem Rev. 2006; 106:3279–3301. [PubMed: 16895328] Carlson EE. ACS Chem Biol. 2010; 5:639–653. [PubMed: 20509672] Böttcher T, Pitscheider M, Sieber SA. Angew Chem Int Ed. 2010; 49:2680–2698.
2. For a definition of bioconjugate chemistry, see: Meares C. Bioconjugate Chem. 1990; 1:1–1.
3. For a definition of “click” chemistry, see: Kolb HC, Finn MG, Sharpless KB. Angew Chem Int Ed. 2001; 40:2004–2021.
4. (a) Rostovtsev VV, Green LG, Fokin VV, Sharpless KB. Angew Chem Int Ed. 2002; 41:2596–2599. (b) Tornøe CW, Christensen C, Meldal M. J Org Chem. 2002; 67:3057–3064. [PubMed: 11975567]
5. (a) Peddibhotla S, Dang Y, Liu JO, Romo D. J Am Chem Soc. 2007; 129:12222–12231. [PubMed: 17880073] (b) Chamni S, He QL, Dang Y, Bhat S, Liu JO, Romo D. ACS Chem Biol. 2011; 6:1175–1181. [PubMed: 21894934] (c) Staub I, Sieber SA. J Am Chem Soc. 2008; 130:13400–13409. [PubMed: 18781750] (d) Zhou CY, Li J, Peddibhotla S, Romo D. Org Lett. 2010; 12:2104–2107. [PubMed: 20387852] (e) Robles O, Serna-Saldívar SO, Gutiérrez-Urbe JA, Romo D. Org Lett. 2012; 14:1394–1397. [PubMed: 22360738] (f) Li J, Cisar JS, Zhou CY, Vera B, Williams H, Rodríguez AD, Cravatt BF, Romo D. Nat Chem. 2013; 5:510–517. [PubMed: 23695633]
6. (a) Fujiwara Y, Dixon JA, Rodríguez RA, Baxter RD, Dixon DD, Collins MR, Blackmond DG, Baran PS. J Am Chem Soc. 2012; 134:1494–1497. [PubMed: 22229949] (b) Fujiwara Y, Dixon JA, O'Hara F, Funder ED, Dixon DD, Rodríguez RA, Baxter RD, Herlé B, Sach N, Collins MR, Ishihara Y, Baran PS. Nature. 2012; 492:95–99. [PubMed: 23201691] (c) Zhou Q, Ruffoni A, Gianatassio R, Fujiwara Y, Sella E, Shabat D, Baran PS. Angew Chem Int Ed. 2013; 52:3949–3952.
7. Cipres A, O'Malley DP, Li K, Finlay D, Baran PS, Vuori K. ACS Chem Biol. 2010; 5:195–202. [PubMed: 20030414]
8. (a) Baran PS, Zografos AL, O'Malley DP. J Am Chem Soc. 2004; 126:3726–3727. [PubMed: 15038721] (b) Baran PS, Li K, O'Malley DP, Mitsos C. Angew Chem Int Ed. 2006; 45:249–252. (c) O'Malley DP, Li K, Maue M, Zografos AL, Baran PS. J Am Chem Soc. 2007; 129:4762–4775. [PubMed: 17375928]
9. Baskin JM, Prescher JA, Laughlin ST, Agard NJ, Chang PV, Miller IA, Lo A, Codelli JA, Bertozzi CR. Proc Natl Acad Sci. 2007; 104:16793–16797. [PubMed: 17942682]

A. Previous work: taggable, conventional functional groups **B. Challenge:** tagging unactivated C-H bonds

How does one tag the following molecules?

C. This work: converting heteroaromatic C-H bonds into linkers for bioconjugation **Figure 1.**

A. Literature precedent involving the tagging of conventional functional groups.⁵ **B.** Identification of a challenge: the tagging of unactivated C-H bonds. **C.** Designing an azide-containing fluoroalkylsulfinate salt that converts a heteroaromatic C-H bond into a linker for bioconjugation.

Figure 2.

A. Synthesis and general reaction of DAAS-Na (**3**). **B.** Formal C–H functionalization of complex natural products. **C.** Formal C–H functionalization of non-natural, biologically active agents that contain heteroaromatic moieties. RSM = Recovered starting material. ^aThe resulting product containing the azide linker has a carbonyl unit *in lieu* of the difluoromethyl group.

A. Synthesis of a drug–antibody conjugate

B. Mass spectral data for synthesized drug–antibody conjugates

Name of small-molecule bioactive agent	Mass of azide-containing analog (Da)	Calculated mass after bioconjugation (Da)	Observed mass after bioconjugation (Da) ^a
camptothecin (1)	523	24337	24337/24336
buspirone (2)	560	24374	24374/24373
sceptrin (6)	771	24585	24585/§§ ^b
papaverine (7)	514	24328	24329/24327
pioglitazone (8)	531	24345	24344/24346
nevirapine (9)	441	24255	24255/## ^c
milrinone (10)	386	24200	24201/24199
bisacodyl (11)	536	25350	##/##
acridine orange (12)	440	24234	24233/24231
atazanavir (13)	879	24693	##/##
loratadine (14)	557	24371	##/24371
bosutinib (15)	704	24518	24520/24518
fasudil (16)	466	24280	24280/24279
varenicline (17)	386	24200	24201/24199
gefitinib (18)	621	24435	24436/24435
selumetinib (19)	631	24445	24445/§§
aciclovir (20)	400	24214	24214/24214
ganciclovir (21)	430	24244	24245/24243
chlorothiazide (22)	470	24284	24285/24284

Figure 3.

A. Appending a monoclonal antibody to an azide-containing bioactive agent. **B.** Mass spectral data that verifies the formation of drug–antibody conjugates. ^aThe two indicated values refer to the mass spectral data arising from two different methods of conjugation (please see the Supporting Information for details); the slight differences in mass between the two methods are deconvolution artifacts. ^bThe symbol §§ indicates that the second method of bioconjugation was not conducted. ^cThe symbol ## indicates that the bioconjugation was unsuccessful.